Clinical trials
Completed trials in Costa Rica
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
179 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 4 |
| 2002 | 9 |
| 2003 | 6 |
| 2004 | 4 |
| 2005 | 23 |
| 2006 | 8 |
| 2007 | 14 |
| 2008 | 15 |
| 2009 | 14 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 6 |
| 2016 | 5 |
| 2017 | 7 |
| 2018 | 8 |
| 2019 | 9 |
| 2020 | 9 |
| 2021 | 10 |
| 2022 | 7 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 179 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 31 |
| Pfizer | 19 |
| GlaxoSmithKline | 17 |
| AstraZeneca | 15 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 10 |
| Novartis Pharmaceuticals | 6 |
| Merck Sharp & Dohme LLC | 5 |
| Novartis | 5 |
| Caja Costarricense de Seguro Social | 4 |
| Bristol-Myers Squibb | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Asthma | 12 |
| Diabetes Mellitus, Type 2 | 12 |
| Arthritis, Rheumatoid | 10 |
| Breast Neoplasms | 8 |
| Carcinoma, Non-Small-Cell Lung | 6 |
| Otitis Media | 6 |
| HIV Infections | 5 |
| Influenza, Human | 5 |
| Whooping Cough | 5 |
| Diabetes Mellitus | 4 |
Trials
Showing 1 to 25 of 179. Each trial links to its page on Pharma Observatory.
79 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.